Piper Jaffray is Bullish Following Strong Q1 by Ctrip.com (CTRP)

Brean Capital Maintains Buy on Ctrip.com (CTRP) Following Strong Q1 Results

Brean Capital maintains a Buy rating on Ctrip.com (NASDAQ: CTRP), and raised the price target to $96.00 (from $70.00), following strong 1Q15 results. CTRP reported net revenue at RMB 2,315mm, exceeding consensus of RMB 2,252mm. Non-Gaap EPS beat consensus by $0.12 with a reported $0.04 EPS. Analyst, Fawne Jiang, said that CTRP guided 2Q15 revenue growth of 45%-50% YoY, above consensus of 43% YoY. Also, management guided a non-GAAP... More

Oppenheimer Upgrades Ctrip.com (CTRP) to Outperform

Oppenheimer upgraded Ctrip.com (NASDAQ: CTRP) from Perform to Outperform with a price target of $80.00, noting secular growth pillars reaccelerate top-line and margins.

Analyst Ella Ji commented, "CTRP's growth pillarsmobile, open platform, yield mgmt., and outbound travelcontinued to drive robust top-line growth in... More

After-Hours Stock Movers 05/13: (SHAK) (ISSI) (CTRP) Higher; (PBYI) (GEVO) (FEYE) Lower (more...)

Puma Biotechnology, Inc. (NYSE: PBYI) 25% LOWER; announced the release of four abstracts on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 to June 2, 2015.

Identive Group (NASDAQ: INVE) 15.2% LOWER; reported Q1 EPS of ($0.54), $0.31 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $19.74 million. First quarter 2015 results included restructuring costs of $0.2 million,... More

Ctrip.com International (CTRP) Tops Q1 EPS by 11c, Sales Beat

Ctrip.com International (NASDAQ: CTRP) reported Q1 EPS of ($0.15), $0.11 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $373 million versus the consensus estimate of $363.31 million.

Business Outlook

For the second quarter of 2015, the Company expects to continue the net... More